MCL1 and hepatocellular carcinoma: Besides transcriptional modulation, MCL-1 expression is also tightly controlled by post-transcriptional modification [32,33], suggesting that proteasomal degradation of MCL-1 could be taking place in regorafenib-treated hepatoma cells.